发明授权
US08207223B2 Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
有权
用于治疗与包含EP4激动剂作为活性成分的骨质量减少相关的疾病的药物组合物
- 专利标题： Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient
- 专利标题（中）： 用于治疗与包含EP4激动剂作为活性成分的骨质量减少相关的疾病的药物组合物
-
申请号： US12549136申请日： 2009-08-27
-
公开(公告)号： US08207223B2公开(公告)日： 2012-06-26
- 发明人: Toru Maruyama , Kaoru Kobayashi , Tohru Kambe , Takayuki Maruyama , Hideyuki Yoshida , Akio Nishiura , Nobutaka Abe
- 申请人： Toru Maruyama , Kaoru Kobayashi , Tohru Kambe , Takayuki Maruyama , Hideyuki Yoshida , Akio Nishiura , Nobutaka Abe
- 申请人地址： JP Osaka
- 专利权人： Ono Pharmaceutical Co., Ltd.
- 当前专利权人： Ono Pharmaceutical Co., Ltd.
- 当前专利权人地址： JP Osaka
- 代理机构： Sughrue Mion, PLLC
- 优先权： JP2001-222148 20010723; JP2001-239895 20010807; JP2002-56449 20020301
- 主分类号： A01N37/08
- IPC分类号： A01N37/08 ; A01N53/00 ; A61K31/215 ; A61K31/19 ; A61K31/557
摘要：
A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).